ClearPoint Neuro

CLPT

Market cap $303M

Overview Fund Activity

10.66 USD

+0.01

0.09%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

10.66

0.00

0%

1 day

0.09%

5 days

1.04%

1 month

-4.99%

3 months

-4.57%

6 months

-21.62%

Year to date

-31.4%

1 year

-10.57%

5 years

91.38%

10 years

173.33%

About: ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.

Employees: 115

Healthcare Medical Devices

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

154% more call options, than puts

Call options by funds: $1.47M | Put options by funds: $579K

119% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 16

12% more capital invested

Capital invested by funds: $97.5M [Q1] → $109M (+$11.8M) [Q2]

3.06% more ownership

Funds ownership: 29.65% [Q1] → 32.71% (+3.06%) [Q2]

5% less funds holding

Funds holding: 101 [Q1] → 96 (-5) [Q2]

13% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 31

See Fund Rankings

Financial journalist opinion

ClearPoint Neuro Announces FDA Clearance Expanding Compatibility of the ClearPoint Prism Neuro Laser Therapy System with 1.5T MRI Scanners

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 4, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that the ClearPoint Prism® Neuro Laser Therapy System ("ClearPoint Prism") received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to include 1.5T MRI guidance in addition to the previously cleared 3T MRI guidance. This expanded labeling could significantly increase ClearPoint Prism's market opportunity within the United States, where 1.5T MRI systems account for approximately 60% of clinical use.1 As the Company considers future development within key markets, 1.5T systems represent over 70% of the global installed MRI base,2 well-positioning ClearPoint Prism for future growth as the company continues to expand internationally.

ClearPoint Neuro Announces FDA Clearance Expanding Compatibility of the ClearPoint Prism Neuro Laser Therapy System with 1.5T MRI Scanners

ClearPoint Neuro: Biopharma Momentum Continues To Build

ClearPoint Neuro's Q2 results were solid; although real upside is likely to be more apparent from 2026 onward. Key catalysts include the launch of GLP services and partner program commercialization, particularly uniQure's Huntington's therapy. Positive partner data and strong system placements could drive ClearPoint's stock higher in 2025.

ClearPoint Neuro: Biopharma Momentum Continues To Build

ClearPoint Neuro, Inc. (CLPT) Q2 2025 Earnings Call Transcript

ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Joseph Michael Burnett - President, CEO & Director Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Anderson Schock - B. Riley Securities, Inc., Research Division Operator Greetings, and welcome to the ClearPoint Neuro, Inc.'s Second Quarter 2025 Financial Results Conference Call.

ClearPoint Neuro, Inc. (CLPT) Q2 2025 Earnings Call Transcript

Zacks Investment Research

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.16 per share a year ago.

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates

ClearPoint Neuro Reports Second Quarter 2025 Results

Record Revenue and Substantial Cash Infusion Highlight the Company's ‘Fast. Forward.' Strategy SOLANA BEACH, CA / ACCESS Newswire / August 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its second quarter ended June 30, 2025.

ClearPoint Neuro Reports Second Quarter 2025 Results

ClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery Portfolio

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / August 4, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced multiple key milestones demonstrating the progression of the Company's Biologics and Drug Delivery Portfolio including first commercial infusions in the United States, additional partners accepted for expedited review, creation of cell and gene infusion ICD-10 codes, and record clinical trial patients treated globally in the month of July. The first commercial treatments for KEBILIDI™ (eladocagene exuparvovec-tneq), a gene therapy approved for pediatric and adult patients with aromatic L-amino acid decarboxylase (AADC) deficiency-a rare, life-threatening neurological disorder, have been performed in the United States using the Company's SmartFlow® Neuro Cannula.

ClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery Portfolio

ClearPoint Neuro to Announce Second Quarter 2025 Results August 12, 2025

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / July 23, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2025 second quarter on Tuesday, August 12th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2025 second quarter on Tuesday, August 12th at 4:30 p.m.

ClearPoint Neuro to Announce Second Quarter 2025 Results August 12, 2025

24/7 Wall Street

Move Over, Magnificent 7: The Frontier 7 Will Redefine Our Future

Key Points in This Article: The Magnificent 7 transformed markets through AI and digital ecosystems, turning a once-pejorative label into a celebrated symbol of innovation and growth.

Move Over, Magnificent 7: The Frontier 7 Will Redefine Our Future

ClearPoint Neuro: Consumables Growth Is Promising

ClearPoint's fundamentals remain strong, despite recent stock weakness. Consumables growth and an expectation of 15-20 system placements in 2025 are illustrative of this strength. The introduction of GLP capabilities and the commercialization of partner programs should lead to stronger growth, beginning in late 2025.

ClearPoint Neuro: Consumables Growth Is Promising

I Missed The Quantum Rally - I Won't Miss The Next One

Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.

I Missed The Quantum Rally - I Won't Miss The Next One

See News Rankings

Charts implemented using Lightweight Charts™